Andrew John Partridge is CCO & VP at Turning Point Therapeutics, Inc. (TPTX). They have made 4 open-market trades across 2 companies since 2021, most recently 2026-10-05.
CIK 0001758838
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GRAL | 155,865 | $22.3M |
| TPTX | 38,361 | $2.9M |
| Total | $25.3M |
Shares reported on the most recent Form 4, priced at the 2026-10-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.